Operations Office

Telephone (507) 266-3549

Date: January 9, 2004

To: Primary Clinical Research Associates

From: Lori K. Kelly
Protocol Development Coordinator

Re: N0272, Phase II Trial of STI-571 in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma

Attached is a revised abstract dated January 5, 2004.

The second sentence of the second paragraph on Page 4 is incorrect (The prescribed dose should be administered, orally, with the total dose for the day divided in half and administered as two split doses approximately 12 hours apart). The sentence should read as follows:

The prescribed dose should be given in a single daily dose of 600 mg.

In addition, there were minor typographical errors edited on this document.

Finally, attached is an updated LASA form. A date field has been added to the top of this form.

Please replace your current versions of the abstract and forms packet cover sheet with these revised versions.

Thank you.

Enclosure